MedTech Acquisition Corporation
MTACW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.09 | -0.09 | -0.00 |
| FCF Yield | -31.02% | -22.88% | -11.15% | -7.76% |
| EV / EBITDA | -4.09 | -3.66 | -6.19 | -11.84 |
| Quality | ||||
| ROIC | -259.13% | -461.31% | 378.82% | -76.39% |
| Gross Margin | 86.06% | 85.93% | 81.79% | 85.80% |
| Cash Conversion Ratio | 1.36 | 0.85 | 0.68 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 33.40% | 30.13% | – | 2,032,773.38% |
| Free Cash Flow Growth | 19.50% | -54.58% | -38.17% | -1,859.35% |
| Safety | ||||
| Net Debt / EBITDA | -0.42 | 0.17 | 0.16 | 1.26 |
| Interest Coverage | -11.70 | -3,384.38 | -36,439.00 | -13.65 |
| Efficiency | ||||
| Inventory Turnover | 1.01 | 1.02 | 1.54 | 0.92 |
| Cash Conversion Cycle | 220.90 | -48.46 | -516.05 | 56.51 |